Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Australian Clinical Labs Ltd ( (AU:ACL) ) has issued an announcement.
Australian Clinical Labs Ltd has announced a change in the interests of a substantial holder, First Sentier Investors. The change affects the voting power and relevant interests in the company’s shares, with implications for the control and management of voting rights. This development could impact the company’s governance and influence its strategic decisions, as substantial holders play a significant role in shaping corporate policies.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Average Trading Volume: 922,602
Technical Sentiment Signal: Sell
Current Market Cap: A$540.1M
For a thorough assessment of ACL stock, go to TipRanks’ Stock Analysis page.